市場調查報告書
商品編碼
1017195

遺傳性血管水腫治療藥的全球市場 (2021年∼2028年)

Global Hereditary Angioedema Therapeutics Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

遺傳性血管性水腫治療的全球市場預計將繼續增長,這得益於對罕見疾病日益增長的興趣以及來自政府和私營公司的研發 (R&D) 資金增加等因素的支持。激肽釋放酶抑製劑就藥物類別、就給藥途徑的靜脈 (IV) 注射和就治療類型的按需治療佔最大佔有率。就地區來看,北美國家是最大的市場,預計將引領未來的市場增長。

本報告提供全球遺傳性血管水腫治療藥的市場相關分析,提供市場規模趨勢預測,及各類藥物·各治療方法類型·各給藥途徑·各地區的詳細趨勢,主要的推動及阻礙市場要素,主要企業的簡介等相關調查。

目錄

第1章 全球遺傳性血管水腫治療藥市場:分析方法·範圍

第2章 全球遺傳性血管水腫治療藥市場:市場定義和概要

第3章 全球遺傳性血管水腫治療藥市場:摘要整理

第4章 全球遺傳性血管水腫治療藥市場:市場動態

  • 對市場的影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球遺傳性血管水腫治療藥市場:產業分析

  • 波特的五力分析
  • PEST分析
  • 流行病學分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球遺傳性血管水腫治療藥市場:新型冠狀病毒感染疾病 (COVID-19)的分析

  • COVID-19對市場的影響分析
    • COVID-19前/過去的市場方案
    • COVID-19中/目前市場方案
    • COVID-19後/未來市場方案
  • COVID-19流行中的價格趨勢
  • 需求與供給的變動階段
  • 政府在COVID-19疫情下的市場相關措施
  • 各製造公司的策略展開情形
  • 結論

第7章 全球遺傳性血管水腫治療藥市場:各類藥物

  • 簡介
    • 市場規模的分析以及與前一年同期相比成長率 (YoY):各類藥物
    • 市場向心力指數:各類藥物
  • 激肽釋放酶抑制劑
    • 簡介
    • 市場規模 (以金額為準,2018年∼2028年)·與前一年同期相比成長率 (YoY) (2020年∼2028年)
  • C1酯酶抑制劑
  • 選擇性緩激肽B2受體拮抗劑
  • 其他

第8章 全球遺傳性血管水腫治療藥市場:各治療方法類型

  • 簡介
    • 市場規模的分析以及與前一年同期相比成長率 (YoY):各治療方法類型
    • 市場向心力指數:各治療方法類型
  • 隨選
  • 預防

第9章 全球遺傳性血管水腫治療藥市場:各給藥途徑

  • 簡介
    • 市場規模的分析以及與前一年同期相比成長率 (YoY):各給藥途徑
    • 市場向心力指數:各給藥途徑
  • 靜脈內 (IV)
  • 皮下
  • 口服

第10章 全球遺傳性血管水腫治療藥市場:各地區

  • 簡介
    • 市場規模 (以金額為準,2018年∼2028年)·與前一年同期相比成長率 (YoY) (2020年∼2028年):各地區
    • 市場向心力指數:各地區
  • 北美
    • 簡介
    • 域內市場固有趨勢
    • 市場規模·與前一年同期相比成長率 (YoY):各類藥物
    • 市場規模·與前一年同期相比成長率 (YoY):各治療方法類型
    • 市場規模·與前一年同期相比成長率 (YoY):各給藥途徑
    • 市場規模·與前一年同期相比成長率 (YoY):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第11章 全球遺傳性血管水腫治療藥市場:競爭情形

  • 主要趨勢與策略
  • 企業佔有率分析
  • 產品的互相比較
  • 值得注意的企業
  • 有顛覆性技術的企業
  • Start-Ups企業

第12章 全球遺傳性血管水腫治療藥市場:企業簡介

  • BioCryst Pharmaceuticals, Inc
    • 企業概要
    • 產品的組合/概要
    • 近幾年趨勢
    • 財務分析:概要
  • CSL Behring LLC
  • Takeda Pharmaceutical Company
  • Pharming Healthcare, Inc
  • Attune Pharmaceuticals, Inc
  • Ionis Pharmaceuticals
  • KalVista Pharmaceuticals, Inc
  • Adverum Biotechnologies, Inc
  • Arrowhead Pharmaceuticals
  • Sanofi
  • Advanced Technology & Industrial Co., Ltd
  • GL Biochem(Shanghai)Ltd
  • Ontores Biotech
  • Shanghai Qiming Biological Technology Co., Ltd
  • Hangzhou Peptidego Biotech Co., Ltd

第13章 關於DataM Intelligence

目錄
Product Code: DMPH3505

Market Overview

The global hereditary angioedema therapeutics market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Hereditary Angioedema is a rare genetic disorder typically characterized by recurrent episodes of severe swelling of the skin and mucous membranes. The swelling most commonly affects the arms, intestinal tract, legs, face, and airway and is usually not itchy.

Market Dynamics

The hereditary angioedema therapeutics market growth is driven by the growing awareness of the treatment for rare diseases, increasing funding for rare genetic diseases and orphan drugs by the government and private companies and the rising cases of hereditary angioedema (HAE) are key factors driving the growth of the market.

Growing awareness of the treatment for rare diseases, is expected to drive the global hereditary angioedema therapeutics market growth

The primary factor attributing to the market's growth is the increasing awareness of the treatment for rare diseases such as hereditary angioedema (HAE). According to the National Organization for Rare Disorders (NORD), the condition is believed to affect about 1 in 50,000 people, and 1 in 150,000 individuals are affected by this disorder worldwide. Angioedema attacks usually occur in sudden, regularly painful swelling in numerous parts of the body, involving the abdomen, extremities, throat, and face. Many organizations are spreading awareness about the diseases and their treatment, like the US Hereditary Angioedema Association, a non-profit organization dedicated to offering HAE patients access to the latest treatment options and dependable, personal support to address symptoms challenges associated with the condition. As per an article published on the National Library of Medicine in October 2020, a study was conducted in 2020 to evaluate the current HAE management and the new treatment options on physician practice patterns over time. The study suggested that physicians reported improvements in HAE management in recent years as per the survey conducted in the United States. Owing to the current therapeutic advances, the reported cases of HAE have improved and reduced concern of adverse treatment effects, and high levels of patient satisfaction have been observed.

Increasing funding for rare genetic diseases and orphan drugs by the government and private companies, is expected to drive the global hereditary angioedema therapeutics market growth

Rising funding for rare genetic diseases and orphan drugs by the government and private companies is also enhancing the interest of the pharmaceutical companies to develop drugs for hereditary angioedema and fuel the market's growth. For example, the Indian Ministry of Health and Family Welfare initiated a National Policy to treat rare diseases in India to expand India's capabilities to treat rare diseases progressively. The Indian ministry released funding of an initial amount of INR 100 crore to treat rare genetic diseases. Hence, the growing funding for research and development for new drugs is boosting the market growth.

For instance, in November 2020, Takeda Pharmaceutical agreed to public funding in Canada of Takhzyro (lanadelumab), its treatment for eligible hereditary angioedema (HAE) patients. In addition, the National Institutes of Health (NIH) also supports research to improve people's health with rare diseases. Many of the 27 Institutes and Centers receives NIH fund for medical research of rare diseases.

Misdiagnosis of the condition due to lack of knowledge of disorder is likely to hamper the market growth

The misdiagnosis of the condition, as common allergies, appendicitis, and irritable bowel syndrome, has steered to an interruption ineffective treatment, which in turn, leads to inadequate treatment being provided to patients, which has had a considerable negative impact on the growth of the global hereditary angioedema therapeutics market.

COVID-19 Impact Analysis

Due to the present pandemic situation, there is a continuous urge to develop a treatment and vaccine; pharmaceutical companies have dedicated their R&D resources entirely to support the COVID-19 vaccine development. In addition, research and development activities for rare diseases, like hereditary angioedema, have been outlined for the time being in R&D laboratories. Moreover, some companies are focusing their R&D resources to understand the effect of COVID-19 in a patient with rare diseases and carrying out Esoteric Testing to determine novel therapies for COVID-19 patients.

Segment Analysis

The kallikrein inhibitors segment is expected to hold largest share in this market segment

Kallikrein Inhibitors are expected to hold the largest share of the segment over the forecast period. Currently, various kallikrein inhibitors are being evaluated owing to their potential to prevent edematous HAE attacks. This comparatively emerging drug therapy class has several potential molecules in the pipelines, which is expected to fuel the market growth.

For instance, BioCryst is developing a novel treatment to treat and prevent angioedema attacks in patients with hereditary angioedema (HAE) and evaluate the molecule APeX-1, an oral once-daily, selective inhibitor of plasma kallikrein. Also, the pharmaceutical companies are rapidly seeking approval in this class of drugs as there is comparatively less competition in this market space.

For instance, in August 2020, the United States Food and Drug Administration approved Takhzyro (lanadelumab), the first monoclonal antibody that targets Kallikrein and is indicated to treat patients 12 years and older types I and II HAE.

The On-demand treatment segment is expected to hold largest share in this market segment

Continued use of on-demand products to manage acute hereditary angioedema attacks is a high-impact rendering driver for the hereditary angioedema therapeutics market.

Moreover, the geographical expansion of companies in newer markets is likely to profound the segment growth. For instance, in September 2018, Shire plc announced that it had received marketing authorization from Japan's Ministry of Health, Labor and Welfare (MHLW) for Firazyr used in the on-demand treatment of hereditary angioedema.

The intravenous segment is expected to hold largest share in this market segment

For medications used to treat hereditary angioedema disorder, intravenous administration has become the most preferred mode of administration. This is because traditional prophylactic medications have historically been given intravenously due to advantages such as convenient dosing and superior efficacy compared to the oral form.

Geographical Analysis

North America region holds the largest market share of global hereditary angioedema therapeutics market

The North American region is expected to serve a large share of the hereditary angioedema market over the forecast period. The market growth is due to key players' presence, increasing awareness programs and research organizations regarding the treatment of the condition, and established healthcare infrastructure. Furthermore, the increasing government initiatives, rising research partnerships, and a robust pipeline are the major growth boosters of the market. For instance, Ionis Pharmaceuticals, a biotechnology company based in California, currently has IONIS-PKK-LRx, a ligand-conjugated (LICA) investigational antisense medicine in its pipeline completed its Phase 2 trials. The company is developing the drug molecule to reduce the production of prekallikrein, or PKK, to treat patients with hereditary angioedema. Also, there is a large number of government and non-government-funded research institutions in this region. For instance, the National Center for Advancing Translational Sciences (NCATS) is wholly focused on esoteric testing for the cure and treatments for rare diseases. NCATS aims to get collaborative projects to study common themes and causes of related diseases to speed the development of treatments. Hence, owing to all the factors mentioned above, the market is anticipated to have lucrative growth in the future.

Competitive Landscape

The global hereditary angioedema therapeutics market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include CSL Behring LLC, Takeda Pharmaceutical Company, Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Attune Pharmaceuticals, Inc., Ionis Pharmaceuticals, KalVista Pharmaceuticals, Inc, Adverum Biotechnologies, Inc, Arrowhead Pharmaceuticals, Sanofi, Advanced Technology & Industrial Co., Ltd, GL Biochem (Shanghai) Ltd, Ontores Biotech, Shanghai Qiming Biological Technology Co., Ltd, Hangzhou Peptidego Biotech Co.,Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In February 2021, KalVista reported positive results in our Phase 2 clinical trial for KVD900 as an oral on-demand treatment for HAE attacks.

Key Companies to Watch

BioCryst Pharmaceuticals, Inc

Overview: BioCryst is a commercial-stage biotech company committed to delivering extraordinary medicines that help patients live ordinary lives. At BioCryst, they are passionate about advancing novel therapeutics for patients with severe and rare diseases. Its US headquarters are located in Durham, North Carolina, and its European headquarters in Dublin, Ireland. Its expertise in drug discovery, clinical development, and regulatory affairs is advancing clinical programs and generating new compounds from its discovery engine.

Product Portfolio: The company is focused primarily on Structure-guided drug design and rare disease therapeutics.

Key Development: In February 2021, BioCryst Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had adopted a positive opinion recommending the approval of ORLADEYO (berotralstat) for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12*years and older.

Why Purchase the Report?

  • Visualize the composition of the hereditary angioedema therapeutics market segmentation by drug class, treatment type and route of administration highlighting the key commercial assets and players.
  • Identify commercial opportunities in hereditary angioedema therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of hereditary angioedema therapeutics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global hereditary angioedema therapeutics market report would provide an access to an approx. 61 market data table, 52 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Hereditary Angioedema Therapeutics Market - By Drug Class

  • C1 Esterase Inhibitor
  • Selective Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others

Global Hereditary Angioedema Therapeutics Market - By Treatment Type

  • Prophylaxis
  • On-demand

Global Hereditary Angioedema Therapeutics Market - By Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral

Global Hereditary Angioedema Therapeutics Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Hereditary Angioedema Therapeutics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Hereditary Angioedema Therapeutics Market - Market Definition and Overview

3. Global Hereditary Angioedema Therapeutics Market - Executive Summary

  • 3.1. Market Snippet by Drug class
  • 3.2. Market Snippet by Treatment type
  • 3.3. Market Snippet by Route of administration
  • 3.4. Market Snippet by Region

4. Global Hereditary Angioedema Therapeutics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing awareness of the treatment for rare diseases
      • 4.1.1.2. Increasing funding for rare genetic diseases and orphan drugs by the government and private companies
    • 4.1.2. Restraints:
      • 4.1.2.1. Misdiagnosis of the condition due to lack of knowledge of disorder
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Hereditary Angioedema Therapeutics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Epidemiology Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. Global Hereditary Angioedema Therapeutics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Hereditary Angioedema Therapeutics Market - By Drug class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 7.1.2. Market Attractiveness Index, By Drug class
  • 7.2. Kallikrein Inhibitor*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. C1 Esterase Inhibitor
  • 7.4. Selective Bradykinin B2 Receptor Antagonist
  • 7.5. Others

8. Global Hereditary Angioedema Therapeutics Market - By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 8.1.2. Market Attractiveness Index, By Treatment type
  • 8.2. On-demand
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Prophylaxis

9. Global Hereditary Angioedema Therapeutics Market - By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration Segment
    • 9.1.2. Market Attractiveness Index, By route of administration Segment
  • 9.2. Intravenous*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Subcutaneous
  • 9.4. Oral

10. Global Hereditary Angioedema Therapeutics Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration

11. Global Hereditary Angioedema Therapeutics Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch
  • 11.5. Company with disruptive technology
  • 11.6. Start Up Companies

12. Global Hereditary Angioedema Therapeutics Market- Company Profiles

  • 12.1. BioCryst Pharmaceuticals, Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. CSL Behring LLC
  • 12.3. Takeda Pharmaceutical Company
  • 12.4. Pharming Healthcare, Inc
  • 12.5. Attune Pharmaceuticals, Inc
  • 12.6. Ionis Pharmaceuticals
  • 12.7. KalVista Pharmaceuticals, Inc
  • 12.8. Adverum Biotechnologies, Inc
  • 12.9. Arrowhead Pharmaceuticals
  • 12.10. Sanofi
  • 12.11. Advanced Technology & Industrial Co., Ltd
  • 12.12. GL Biochem (Shanghai) Ltd
  • 12.13. Ontores Biotech
  • 12.14. Shanghai Qiming Biological Technology Co., Ltd
  • 12.15. Hangzhou Peptidego Biotech Co., Ltd

LIST NOT EXHAUSTIVE

13. Global Hereditary Angioedema Therapeutics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us